Domestic bio stocks are showing a differentiated market trend by individual stock. While Invtage Lab and Olix recorded strong gains, Rokit Healthcare, JW Pharmaceutical, and Antrogen reversed into decline.

Gaining Stocks

During the morning session on the 1st, Invtage Lab is trading at 42,850 won, up 3,350 won (8.48%) from the previous trading day. It temporarily surged to 44,300 won intraday, confirming strong buying pressure. Expectations for new drug development have attracted investor interest, driving up the price.

Olix also recorded 172,000 won, up 16,400 won (10.54%), showing a surge of more than 10%. The intraday high reached 179,400 won, leading the gains within the biotech sector.

Declining Stocks

Meanwhile, Rokit Healthcare traded at 43,250 won, down 1,750 won (3.89%), as profit-taking sell orders emerged. JW Pharmaceutical and Antrogen also each showed declines in the 4% range.

Market Outlook

The market diagnosis suggests that amid an overall improvement in investment sentiment for the biotech sector, stock price differentiation among individual companies is deepening depending on clinical trial progress, technology transfer possibilities, and R&D achievements. Going forward, individual company momentum such as clinical result announcements, technology transfer deals, and R&D achievements is drawing attention as the key variable that will determine stock price direction.

[This article was written with the assistance of AI. This article is not a recommendation to invest, and the final decision and responsibility for investments lie with the investor.]